- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05801978
Systems Biological Assessment of the Durability of Vaccine Responses (DARPASB)
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown.
This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the influenza vaccine generates an immunity that wanes quickly with no long-lasting protection. Currently, the duration of immune protection for new vaccines is difficult to predict during vaccine product development and can only be ascertained by a "wait and see" approach. This is due, in part, to the fact that some of the signals that activate a durable immune system protection remain unknown.
This study aims to provide a better understanding of this problem by vaccinating willing participants with either the FDA-approved yellow fever vaccine or the quadrivalent influenza vaccine and collecting baseline and follow-up biologic samples to compare how the immune system reacts. The biologic samples will be collected from the blood (where antibodies are), the lymph nodes (where immune cells that make antibodies are present), and from the bone marrow (where long-lived cells that secrete antibodies are found). This study will take place at the Hope Clinic of Emory University.
The participants who express interest to ads for this research will be contacted by study staff who will provide further information about the study and conduct a primary evaluation of the eligibility criteria. If the participant is interested and verifies the eligibility criteria, a screening visit will be scheduled during which the study staff will go over the informed consent form with the participant. Other study procedures will be performed during this screening visit if the participant agrees to sign the informed consent form.
This study will include a screening visit, a vaccination visit, tissue sampling visits and a series of follow-up visits. During the tissue sampling visits, one or two procedures will be performed: A) Lymph node sampling during which an expert, guided by imaging, will take fine needle aspirates/ core biopsies from a lymph node. B) Bone marrow aspirate during which an expert will aspirate a small amount of bone marrow. Lymph node sampling procedures will be performed no more than two times each and bone marrow aspirations will be performed no more than three times each on the same participant. Other study procedures include a collection of medical history and medications taken, a urine pregnancy test for participants who are biologically able to become pregnant, a recording of vital signs, and a collection of adverse events that the participant experiences during their participation in the study. An HIV test is obtained as well at screening. Memory Aid will be completed by each participant.
The blood, lymph node, and bone marrow samples collected during this study will be stored and tested to evaluate how the immune system has responded to the vaccination over time. The remaining unused samples will be stored for use in future research.
This research will help advance the knowledge the study team has of how the immune system reacts to different vaccines, which will in turn, enable to identification of the factors that help predict the extent of durability of protection gained from a specific vaccine. This will also have a major impact on the way future vaccines are developed to provide long-lasting immunity against infections.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Nadine Rouphael, MD
- Phone Number: 404-712-1435
- Email: nroupha@emory.edu
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory University Hospital
-
Contact:
- Nadie Rouphael, MD
- Phone Number: 404-712-1435
- Email: nroupha@emory.edu
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Winship Cancer Institute
-
Contact:
- Nadine Rouphael, MD
- Phone Number: 404-712-1435
- Email: nroupha@emory.edu
-
Decatur, Georgia, United States, 30030
- Recruiting
- The Hope Clinic of Emory University
-
Contact:
- Nadine Rouphael, MD
- Phone Number: 404-712-1435
- Email: nroupha@emory.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to understand and give informed consent.
- Age 18-50 years.
- Participants agree not to take any live vaccines 30 days before or after (14 days for inactivated) vaccination.
- Women of child bearing potential must agree to use effective birth control for the first 3 months of the study. A negative urine pregnancy test must be documented prior to vaccination and prior to tissue sampling procedures.
Exclusion Criteria:
- History of allergy or serious adverse reaction, including Guillain-Barré syndrome, to a vaccine or vaccine products.
- History of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
- History of Hepatitis B or Hepatitis C infection.
Chronic clinically significant medical problems that could affect the immune response, require medication that would affect the immune response, or have signs or symptoms that could be confused with reactions to vaccination, including (but not limited to):
- Insulin dependent diabetes
- Severe heart disease (including arrhythmias)
- Severe lung disease
- Severe liver disease
- Severe kidney disease
- Grade 4 hypertension (*Grade 4 hypertension per CTCAE criteria is defined as life-threatening consequences (e.g., malignant hypertension, transient or permanent neurologic deficit))
- Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of uncontrolled autoimmune disorder.
- Pregnancy or breast feeding, or plans to become pregnant in the first 3 months of study participation.
- Receipt of blood products or immune globulin product within the prior 3 months.
- Active duty military.
- History of excessive alcohol consumption, drug use, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial.
Additional Exclusion Criteria for YF-17D Arm
- History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, or Japanese encephalitis vaccination or infection.
- Previous residence in a country where there is a risk of yellow fever virus (YFV) transmission
- History of allergy to eggs, chicken, or gelatin.
Additional Exclusion Criteria for QIV Arm
- History of influenza infection within the same influenza season.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: YF-17D Vaccination
Yellow Fever Vaccine (YF-17D) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for YF-17D per the Centers for Disease Control and Prevention (CDC) guidelines.
Participants will then receive the YF-17D vaccine.
They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions.
They will also be given the International Certificate of Vaccination documenting receipt of YF-17D.
|
The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial.
The vaccine is prepared by culturing the 17D-204 strain of yellow fever virus, contains sorbitol and gelatin as a stabilizer, and contains no preservative.
Each vial of vaccine is supplied with a separate vial of sterile diluent, which contains sodium chloride injection USP (United States Pharmacopeia) without a preservative.
|
Experimental: QIV Vaccination
Quadrivalent seasonal influenza vaccine (QIV) vaccination: Eligible participants will be asked to read the Vaccine Information Sheet for QIV per the CDC guidelines.
Participants will then receive QIV.
They will be observed for a minimum of 20 minutes for any immediate hypersensitivity reactions.
|
The FDA-approved quadrivalent seasonal influenza vaccine contains four distinct strains: two influenza A viruses and two influenza B viruses.
The approved seasonal QIV will be purchased from the manufacturer to be given for each season of influenza.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Magnitude of neutralizing antibody (nAB) response against YF-17D in blood
Time Frame: Up to 270 days after vaccination
|
Magnitude of neutralizing antibody responses against YF-17D at 270 days after vaccination among participants who receive YF-17D.
|
Up to 270 days after vaccination
|
Magnitude of neutralizing antibody (nAb) response against QIV in blood
Time Frame: Up to 270 days after vaccination
|
Magnitude of neutralizing antibody responses against influenza vaccine strains at 270 days after vaccination among participants who receive QIV.
|
Up to 270 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of adverse events until day 28
Time Frame: Until day 28 after vaccination with YF-17D or QIV
|
Adverse events of grade 2 or higher (AE, defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of vaccine, without any judgment about causality) will be identified during questioning or examination of participants during study visits or receiving a safety contact from a participant.
|
Until day 28 after vaccination with YF-17D or QIV
|
Severity of adverse events until day 28
Time Frame: Until day 28 after vaccination with YF-17D or QIV
|
Adverse events (AE) will be graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0
|
Until day 28 after vaccination with YF-17D or QIV
|
Frequency of serious adverse events until day 270
Time Frame: Until day 270 after vaccination with YF-17D or QIV
|
Serious adverse events (SAE, defined as an AE that in the view of the investigator results in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect) will be identified during questioning or examination of participants during study visits or receiving a safety contact from a participant any time during the study.
|
Until day 270 after vaccination with YF-17D or QIV
|
Severity of serious adverse events until day 270
Time Frame: Until day 270 after vaccination vaccination with YF-17D or QIV
|
SAE will be graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
|
Until day 270 after vaccination vaccination with YF-17D or QIV
|
Frequency of adverse events until day 7 after lymph node sampling and/or bone marrow aspiration
Time Frame: Until day 7 after lymph node sampling and/or bone marrow aspiration
|
Adverse events (AE) of grade 2 or higher will be identified during questioning or examination of participants during study visits, telephone calls 7 +/- 3 days after lymph node sampling and/or bone marrow aspiration, or receiving a safety contact from a participant.
|
Until day 7 after lymph node sampling and/or bone marrow aspiration
|
Severity of adverse events until day 7 after lymph node sampling and/or bone marrow aspiration
Time Frame: Until day 7 after lymph node sampling and/ or bone marrow aspiration
|
SAE will be graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 5.0.
|
Until day 7 after lymph node sampling and/ or bone marrow aspiration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nadine Rouphael, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00004930
- #W911NF2320019 (Other Grant/Funding Number: Defense Advanced Research Project Agency)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaccine Response
-
University of California, IrvineMassachusetts General Hospital; Beckman Laser Institute University of California...CompletedVaccine Response ImpairedUnited States
-
Merck Sharp & Dohme LLCCompletedVaccine Response Impaired
-
The University of Texas Health Science Center at...Suspended
-
Serum Institute of India Pvt. Ltd.PATHCompletedImmune Response to MMR VaccineIndia
-
Touro University, CaliforniaSanofiCompletedPatient Response to Fluzone ID VaccineUnited States
-
University of Colorado, DenverRecruitingKidney Transplant Recipient Response to Shingrix VaccineUnited States
-
University Hospital, Basel, SwitzerlandCompletedAllogeneic Stem Cell Transplantation | Vaccine Response ImpairedSwitzerland
-
PfizerCompletedSafety | Immunization | 13-valent Pneumococcal Vaccine | Antibody ResponseFrance
-
Persephone BiosciencesTerminatedVaccine Adverse Reaction | Vaccine Response ImpairedUnited States
-
Chulalongkorn UniversityBioNet-Asia; Chula Clinical Research Center (Chula CRC), Faculty of Medicine... and other collaboratorsRecruitingSafety of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response of 25 ug of ChulaCov19-BNA159 mRNA Vaccine | Safety of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Tolerability of 50 ug of ChulaCov19-BNA159 mRNA Vaccine | Immune Response... and other conditionsThailand
Clinical Trials on Live Attenuated Yellow Fever 17D Vaccine
-
London School of Hygiene and Tropical MedicineNot yet recruitingYellow Fever
-
National Institute of Allergy and Infectious Diseases...CompletedAtopic DermatitisUnited States
-
University of Sao Paulo General HospitalCompletedRheumatoid Arthritis | Systemic Sclerosis | Granulomatosis With Polyangiitis | Juvenile Idiopathic Arthritis | Sjogren's Syndrome | Takayasu Arteritis | Spondyloarthritis | Juvenile Dermatomyositis | Mixed Connective Tissue Disease | Systemic Lupus | Inflammatory MyopathyBrazil
-
SanofiCompletedJapanese Encephalitis | Yellow FeverAustralia
-
Singapore General HospitalCompleted
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes...Recruiting
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
Changchun Keygen Biological Products Co., Ltd.Guangdong Provincial Institute of Biological Products And Materia MedicaCompletedJapanese Encephalitis | ChickenpoxChina
-
Leiden University Medical CenterThe International Society of Travel MedicineRecruiting
-
EpicentreKenya Medical Research InstituteCompletedYellow FeverUganda, Kenya